Key result
CMR effectively characterizes tissue and cardiac function in high cardiometabolic risk patients despite lacking screening approval.
Why the study?
CMR is not approved clinically for routine screening for cardiovascular disease among patients with increased cardiometabolic risk despite its potential for tissue characterization and cardiovascular screening.
Cardiac MRI offers detailed tissue characterization that may influence future cardiovascular risk assessment in patients with cardiometabolic risk, pending further clinical research.
May aid risk stratification in cardiometabolic patients; hypothesis-generating and should not yet change screening practice.
Cardiac MRI (CMR) has rich potential for future cardiovascular screening even though not approved clinically for routine screening for cardiovascular disease among patients with increased cardiometabolic risk. Patients with increased cardiometabolic risk include those with abnormal blood pressure, body mass, cholesterol level, or fasting glucose level, which may be related to dietary and exercise habits. However, CMR does accurately evaluate cardiac structure and function. CMR allows for effective tissue characterization with a variety of sequences that provide unique insights as to fibrosis, infiltration, inflammation, edema, presence of fat, strain, and other potential pathologic features that influence future cardiovascular risk. Ongoing epidemiologic and clinical research may demonstrate clinical benefit leading to increased future use.
No takes yet. Share an insight, caveat, or question.
Philip et al. (2021) conducted a review in Increased cardiometabolic risk. Cardiac MRI was evaluated. Cardiac MRI provides effective tissue characterization and evaluation of cardiac structure and function for patients with increased cardiometabolic risk, despite lacking approval for routine screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: